Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 2,287 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasted State Clear all

Conditions: Cognitive Ability, General, Dietary Modification
Interventions: SLOW Carbohydrate, MEDIUM Carbohydrate, FAST Carbohydrate; Other
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 9 Years to 10 Years
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Obesity
Interventions: Time Restricted Eating (TRE); Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 25 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Ribavirin 200 mg tablets, COPEGUS™; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Healthy Volunteers
Interventions: Tacrolimus; Drug
Lead sponsor: Food and Drug Administration (FDA); Federal
Eligibility: 18 Years to 59 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Achalasia
Interventions: Barostat; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Non-Insulin-dependent Diabetes Mellitus
Interventions: placebo, 3.4 g psyllium BID, 6.8g psyllium BID; Dietary Supplement
Lead sponsor: Procter and Gamble; Industry
Eligibility: 36 Years to 80 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1988 – 1990
U.S. locations: 2
States / cities: Miami, Florida • Minneapolis, Minnesota

Conditions: KRAS Mutant Non-Small Cell Lung Cancer, Solid Tumors
Interventions: Palbociclib, PD-0325901; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bulimia Nervosa
Interventions: Fasting state, Fed state, Magnetic Resonance Imaging; Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-05161704 or placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Type 1 Diabetes
Interventions: LY900014, Insulin Degludec; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Atlanta, Georgia • West Des Moines, Iowa • Minneapolis, Minnesota

Conditions: Gout
Interventions: D-0120; Drug
Lead sponsor: InventisBio Co., Ltd; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Healthy
Interventions: Propranolol Hydrochloride Extended-Release Capsules 160 mg, Inderal® LA Capsules 160 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Type2 Diabetes Mellitus, Cardiovascular Diseases
Interventions: Early Total Caloric Intake, Late Total Caloric Intake, Extended Overnight Fast; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 30 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hepatitis C
Interventions: ABT-072, Placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Waukegan, Illinois

Conditions: Conduct Disorder, Anti-Social Behavior
Interventions: Fast Track; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 6 Years to 8 Years
Enrollment: 891 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1991 – 2029
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Invasive Breast Carcinoma
Interventions: Short-Term Fasting, Chemotherapy, Biospecimen Collection, Questionnaire Administration; Other · Drug · Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 5
States / cities: Cherry Hill, New Jersey • Sewell, New Jersey • Philadelphia, Pennsylvania + 1 more

Conditions: Hepatic Failure, Hepatic Impairment, Chronic Hepatitis C Infection With Hepatic Coma
Interventions: 2.0mg Buprenorphine/0.5mg Naloxone, Promethazine; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Hialeah, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Healthy Participants
Interventions: Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 2, Laroprovstat Dose X STP, Rosuvastatin Dose 1 STP, Rosuvastatin Dose 2 STP; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Brain Metastases, Adult, Brain Metastases, Brain Cancer
Interventions: 18F fluciclovine; Drug
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Fasting
Interventions: oral fructose challenge; Dietary Supplement
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pancreatitis, Pancreatitis, Acute, Pancreatitis, Chronic, Pancreas Disease, Acute Recurrent Pancreatitis
Interventions: Intermittent Fasting, No intermittent fasting; Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Healthy
Interventions: Propranolol Hydrochloride Extended Release Capsules 160 mg, INDERAL® LA 160 mg Capsules, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Obesity
Interventions: Alternate day fasting; Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes Type 2
Interventions: Insulin-Levemir, Exenatide-Bayetta, Insulin-Levemir and Exenatide-Bayetta, SenseWear Pro3® armband, DexCom CGM; Drug · Device
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Search by objective public record fields.

The Acute Effects Fortified Nutritional Supplementation on Childhood Cognition

Time Restricted Eating for Weight Loss Maintenance

Ribavirin 200 mg Tablets Under Fasting Conditions

Bioequivalence Study of Tacrolimus in Healthy Volunteers

Sensorimotor Dysfunction in Achalasia

Study of Metamucil on Blood Glucose and HbA1c in Type II NIDDM Subjects

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Changes in Inhibition and Valuation After Eating

A Single Dose Study Of PF-05161704 In Healthy Volunteers

A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes

D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers

Fasting Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg

Behavioral Chronotype: Impact on Sleep and Metabolism

Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072

Multisite Prevention of Conduct Problems (Fast Track)

Time Restricted Eating for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before Surgery

Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects

A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults

Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery

The Effects of Increased Fructose Ingestion on FGF-21 Levels in Humans

Intermittent Fasting for Pancreatitis

A Relative Bioavailability Study of Propranolol HCl 160 mg Tablets Under Non-fasting Conditions

Alternate Day Fasting Combined With a High Protein Background Diet

Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment